Last reviewed · How we verify
NCT02156115
Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
trial in Lymphangiomatosis in 14 participants. Terminated before completion.
1 April 2024
Quick facts
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 14 |
| Start date | 23 March 2015 |
| Primary completion | 1 April 2024 |
| Estimated completion | 1 April 2024 |
| Sites | 1 location across United States |
Conditions studied
- Lymphangiomatosis — all drugs for Lymphangiomatosis →
- Lymphedema — all drugs for Lymphedema →
- Lymphangiectasia — all drugs for Lymphangiectasia →
- Pulmonary Lymphangiectasia — all drugs for Pulmonary Lymphangiectasia →
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Who can join
Adults 2 to 90, any sex, with Lymphangiomatosis or Lymphedema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: \- Lymphatics are a type of vessel, similar to arteries and veins. Lymphatic disorders happen when these vessels don t work properly. Researchers want to look for a relationship between lymphatic disorders and variations of certain genes found in the lung, blood, and other places in the body. Objective: \- To learn more about lymphatic disorders and evaluate how genetic factors affect lymphatic disorders. Eligibility: * People ages 2 90 who have a lymphatic disorder or relatives of people with lymphatic disorders. * Healthy volunteers 18 and older. Design: * Participants may have 1 2 visits a year, or more as needed. The study is expected to last 5 years. Visits may last 1 5 days. Participants may have lab tests, medical history, and physical exam at each visit. * Participants may have blood testing that includes genetics tests, and urine tests. They may have nose and throat cultures, saliva collection, and cheek swabs to collect samples. * Participants may have a skin biopsy and have blood taken from an artery. * Participants may have breathing tests and be studied while exercising. * Participants may have an electrocardiogram. Electrodes will be placed on their chest, tracing heart rhythms. They may also have chest X-rays. * Participants may have a bronchoscopy. A thin, flexible instrument will be passed through the nose or mouth, into the lung. A tissue sample will be taken. * Participants who have lymphatic disease or have a relative with it may also have: * CT scans. They will lie on a table and hold their breath while their chest is scanned. * MRI. They will lie flat on a table that slides in and out of a scanner. * ultrasound. A probe is rolled around outside the abdomen. * removal of fluid around the lungs, chest, and abdomen.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02156115
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Heart, Lung, and Blood Institute (NHLBI) trials
Trials by the same sponsor.
- NCT07566494 — Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease · Phase 1 · not yet recruiting
- NCT07137455 — EDEN Intracardiac Electrogram Recording and Classifying System · NA · enrolling by invitation
- NCT05372627 — NHLBI-Emory Advanced Cardiac CT Reconstruction · not yet recruiting
- NCT07516379 — GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejecti · not yet recruiting
- NCT06948097 — Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fost · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02156115 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Heart, Lung, and Blood Institute (NHLBI)
- Last refreshed: 11 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02156115.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing